Petros Pharmaceuticals(PTPI)

Focus: Petros Pharmaceuticals is a public-stage company focused on men's health and neurology, with minimal commercial traction ($6M revenue in FY2024).

Neurology

Profile data last refreshed 20h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Petros Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Petros Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

10 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$6M

FY2024

Pipeline & Clinical Trials

Cold environment participants with spinal cord injury

Spinal Cord Injuries

N/A

Clinical Trials (1)

NCT04215939Assessment of Vasomotion of People With Spinal Cord Injury

N/A

Help build intelligence for Petros Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides liquidity and potential upside through stock options, unlike private equity-backed biotech.
41% R&D intensity signals commitment to pipeline development despite minimal commercial revenue.
Early-stage positioning in men's health and neurology may offer opportunity to shape a clinical program from ground up.

Watch Out For

Zero active job openings and no headcount data suggest minimal hiring or possible workforce constraints despite public status.
Negative net income of -$8.2M (FY2024) and -$20M (FY2023) with flat $6M revenue indicates pre-commercial burn without clear path to profitability.
Pipeline of 10 trials lacks traditional IND/Phase development nomenclature and appears investigator-initiated rather than company-sponsored programs.
Delayed 2025 10-K SEC filing (March 2026) signals administrative or financial reporting concerns.
Only $13M cash position with $2M annual R&D spend supports ~6.5 years of burn at current rates, assuming no additional funding.

Generated by Claude from Petros Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Effects of an eight weeks aerobic exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue

Obese

N/A

Clinical Trials (1)

NCT04039685The Effects of Chronic Exercise on UCP1 Gene in Human White Adipose Tissue

N/A

Work/ rest scenario

Risk of Heat Stress

N/A

Clinical Trials (1)

NCT04160728Occupational Heat Stress on Workers' Productivity

N/A

Shuttle run test

Risk of Heat Stress

N/A

Clinical Trials (1)

NCT04241900Effect of Aging and Aerobic Fitness Level on Heat Dissipation

N/A

Radiation and warm environment

Heat Stress

N/A

Clinical Trials (1)

NCT04160741Effects of Solar Radiation on Human Function and Cognition

N/A

Thermal stress and performance using a pre-cooling protocol

Risk of Heat Stress

N/A

Clinical Trials (1)

NCT04197375Impact of Pre-cooling in Adolescent Tennis Athletes

N/A

Colostrum supplementation for bone loss

Osteopenia

N/A

Clinical Trials (1)

NCT04040010The Effects of Bovine Colostrum in Bone Metabolism in Humans

N/A

Environmental Temperature and White Adipose Tissue in Cancer Patients

Cancer Patients

N/A

Clinical Trials (1)

NCT04037410Environmental Temperature and White Adipose Tissue in Cancer Patients

N/A

Exercise with cooling

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT04125628Exercise on Multiple Sclerosis Patients

N/A

Cold exposure

Obesity

N/A

Clinical Trials (1)

NCT04037371Environmental Temperature and Human White Adipose Tissue

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2021

Portfolio: 10 clinical trials

Top TAs: Metabolic Diseases, Neurology, Oncology

Publications: 8 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Metabolic Diseases

2 pipeline

Neurology

1 pipeline

Oncology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Net Income

-$14M

Cash

$2M

Source: SEC 10-K Filing

Risk Signals

No layoff data available; delayed 10-K filing and zero active job openings suggest possible restructuring or administrative distress.

SEC filing delays, flat revenue, accelerating losses, and absence of hiring create material risk of significant organizational changes or insolvency within 12–24 months.

Research Publications(8)

Recent peer-reviewed publications with author affiliations at this company

Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in patients with severe asthma prior to biologic initiation in real-life (STAR).

The World Allergy Organization journal

2025

PMID:40524942

Diagnosing and Treating Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease as Part of the Still's Disease Continuum.

Mediterranean journal of rheumatology

2024

PMID:38756937